Persistence of Beta- Blocker Treatment After a Heart Attack (PBH)
HEDIS Measure
Persistence of Beta- Blocker Treatment After a Heart Attack (PBH)
Line of business: Commercial Medicaid Medicare
Data Collection Method: Administrative (Claims)
Measure Description
The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.
Numerator Compliance
At least 135 days of treatment with beta-blockers during the 180-day measurement interval. This allows gaps in medication treatment of up to a total of 45 days during the 180-day measurement interval.
Beta-Blocker Medications
| Description | Prescriptions |
|---|---|
| Noncardioselective beta-blockers | Carvedilol, Labetalol, Nadolol, Pindolol, Propranolol, Timolol, Sotalol |
| Cardioselective beta-blockers | Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol |
| Antihypertensive combinations | Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, Hydrochlorothiazide-propranolol |